JCR Japan College of Rheumatology-
有限責任中間法人 日本リウマチ学会
  会員専用ページ

トップページ
学会案内
沿革
定款
役員・委員会
名誉会員・評議員
学術集会
総会学術集会
歴代総会・学術集会
支部・学術集会
学会教育研修会
国際関連学会
認定制度
リウマチ専門医
リウマチ指導医
教育施設
学会出版物
学会誌MR
NLリウマチ
リウマチ学用語集
会員手続き
本サイトについて
よくある質問
関連リンク集
サイトマップ
プライバシー

MODERN RHEUMATOLOGY Vol.14 No.1

>MR14-1

Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis
Shumpei Yokota1 , Takako Miyamae1, Tomoyuki Imagawa1, Naomi Iwata1, 2, Shigeki Katakura1 and Masaaki Mori1
(1) Department of Pediatrics, Yokohama City University School of Medicines, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
(2) Department of Rheumatic Diseases, Aichi Childrens Health and Medical Center, Obu, Japan
Received: 22 April 2003 Accepted: 07 August 2003

Full Text
  > Click Here (member's only)

Abstract

Abstract Systemic-onset juvenile idiopathic arthritis (JIA) is a severe and steroid-dependent disease, which sometimes progresses to the fatal disease macrophage activation syndrome. An investigation of inflammatory cytokine levels revealed increases in IL-6 in serum of systemic-onset disease patients. Continuously elevated levels of IL-6 in serum may play a important role in manifesting the clinical symptoms and signs of systemic-onset JIA, including spiking fever, rash, arthritis, and serositis. The characteristic fever spikes parallel IL-6 levels. Long-term exposure to high levels of IL-6 in children results in severe growth impairment, which was strongly suggested by the recent establishment of IL-6 transgenic mice. To avoid disease progression to macrophage activation syndrome and the adverse effects of high-dose corticosteroids, it might be reasonable to inhibit the formation of IL-6/IL-6R complex in order to block the binding to gp130 receptor, a biologically active receptor for IL-6. This review will provide evidence of the relationship between IL-6 homeostasis and systemic-onset JIA, and our recent trials of anti-IL-6R antibody (MRA) for children with acute systemic disease intractable to long-term and high-dose corticosteroid therapy. MRA could be a therapeutic modality for children with systemic-onset JIA intractable to high-dose corticosteroids.
 
Key words
Key words Antirheumatic drug - Cytokine - Cytokine-inducible proteins - Inflammation - Juvenile idiopathic arthritis (JIA)
 
一覧に戻る

Copyright Japan College of Rheumatology All rights reserved.